作者
EREN GÜNDÜZ, Hakkı Kırkızlar, ELİF ÜMİT, Sedanur Gülsaran, VİLDAN ÖZKOCAMAN, FAHİR ÖZKALEMKAŞ, ÖMER CANDAR, TUĞRUL ELVERDİ, Selin Küçükyurt, SEMRA PAYDAŞ, Özcan Çeneli, Sema Karakuş, Senem Maral, Ömer Ekinci, Yıldız İpek, Cem Kis, Zeynep Güven, Aydan Akdeniz, Tiraje Celkan, Ayşe Küçükdiler, Gülsüm Çağlıyan, Ceyda Şengöz, Ayşe Karataş, TUBA Bulduk, Alper Özcan, Fatma Apak, Aylin Canbolat, İbrahim Kartal, Hale Ören, Ersin Töret, Gül Özdemir, Şule Öztürk
发表日期
2022
期刊
Turkish Journal of Hematology
卷号
39
期号
2
简介
© 2022 by Turkish Society of Hematology.
Objective
Castleman disease (CD) is a rare disease also known as angiofollicular lymph node hyperplasia. The two main histological subtypes are the hyaline vascular and plasma cell variants. It is further classified as unicentric CD (UCD) or multicentric CD (MCD) according to the anatomical distribution of the disease and the number of lymph nodes involved. The aim of this multicenter study was to evaluate all cases of CD identified to date in Turkey to set up a national registry to improve the early recognition, treatment, and follow-up of CD.
Materials and Methods
Both adult (n=130) and pediatric (n=10) patients with lymph node or involved field biopsy results reported as CD were included in the study. Patients’ demographic information, clinical and laboratory characteristics, imaging study results, treatment strategies, and clinical outcomes were evaluated retrospectively.
Results
A total of 140 patients (69 male and 71 female) with a diagnosis of UCD (n=73) or MCD (n=67) were included. The mean age was 39 years in the UCD group and 47 years in the MCD group. Female patients were more common in the UCD group. The most common histological subtype was hyaline vascular for both UCD and MCD patients. Asymptomatic patients were more common in the UCD group. Anemia, elevations of acute phase reactants, and hypoalbuminemia were more common in the MCD group. The most commonly used treatment strategies for UCD were surgical excision, rituximab, and radiotherapy, respectively. All UCD patients were alive at a median of 19.5 months of follow-up. The most commonly used …
学术搜索中的文章